Dr. Oza discusses reframing diagnoses for conditions commonly seen in adults which are very uncommon in children, including lipomas and epidermal inclusion cysts.

Dr. Harper discusses working with a young man who showed improvement of acne of the mid-face with isotretinoin treatment, who eventually developed large fluctuant nodules

Dr. Culton discusses diagnosing non-blistering clinical phenotypes of pemphigoid and pemphigus and the increasingly common prevalence of drug-induced pemphigoid.

Dr. Zirwas discusses clinical impacts of notable additions to the dermatology literature this year—including 1% diclofenac gel for acne keloidalis nuchae and pseudofolliculitis barbae and

Dr. Marghoob discusses dysplastic nevi as markers of increased risk for melanoma, then elaborates on optimal approaches to detection, screening, monitoring, and biopsy of these

Melodie Young discusses the differences in disease presentation between children with PsA and adults with PsA, including differences in symptom onset and disease progression, and

Dr. Oza discusses new methods for detecting preclinical AD in infants, new insights into early-onset AD predictive of future food allergies, and a variety of

Dr. Chovatiya discusses the identification, causes, the variety of manifestations and phenotypes, and treatment approaches for chronic hand eczema.

Dr. Hawkes provides an overview of the difference between chronic and acute urticaria, then further differentiated chronic urticaria as being spontaneous or attributable to a

Dr. Harper discusses a case of neurogenic rosacea—a rare form of rosacea categorized not by papules and pustules, but mainly by redness, burning, and stinging.

Dr. Shaw discusses type 1 interferon antagonism as a promising treatment avenue for two connective tissue diseases—recalcitrant cutaneous lupus and dermatomyositis.

Dr. Zirwas shares how to best explain environmental triggers of AD to patients who experience disease onset later in life.

Dr. Hawkes discusses the influx of new and emerging oral therapies that have demonstrated success in treating psoriasis.

Dr. Shaw discusses considering domains of disease in patients with PsA, such as possible comorbidities and affected organ systems, before choosing a treatment.

Melodie Young discusses the psychological impact of psoriatic disease on pediatric patients.